CA1336504C - Technique de traitement photodynamique - Google Patents

Technique de traitement photodynamique

Info

Publication number: CA1336504C
Authority: CA; Canada
Prior art keywords: tumor; light source; photosensitive compound; light; hpd
Prior art date: 1987-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 578809

Other languages

English (en)

Inventor

Robert Arthur Gatenby

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MedImmune LLC

Original Assignee

MedImmune LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-01

Filing date

1988-09-29

Publication date

1995-08-01

1988-09-29 Application filed by MedImmune LLC filed Critical MedImmune LLC

1995-08-01 Application granted granted Critical

1995-08-01 Publication of CA1336504C publication Critical patent/CA1336504C/fr

2012-08-01 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract description 19
230000001225 therapeutic effect Effects 0.000 title description 2
206010028980 Neoplasm Diseases 0.000 claims abstract description 103
208000024891 symptom Diseases 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 49
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 9
210000004881 tumor cell Anatomy 0.000 claims description 4
238000010521 absorption reaction Methods 0.000 claims description 3
229920002313 fluoropolymer Polymers 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims 1
230000009467 reduction Effects 0.000 abstract description 18
210000005036 nerve Anatomy 0.000 abstract description 2
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
210000001519 tissue Anatomy 0.000 description 8
230000037431 insertion Effects 0.000 description 7
238000003780 insertion Methods 0.000 description 7
201000009030 Carcinoma Diseases 0.000 description 6
230000006872 improvement Effects 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000001994 activation Methods 0.000 description 5
230000005540 biological transmission Effects 0.000 description 5
238000002591 computed tomography Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004809 Teflon Substances 0.000 description 4
229920006362 Teflon® Polymers 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000035602 clotting Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
206010030124 Oedema peripheral Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
210000000588 acetabulum Anatomy 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
150000004036 bacteriochlorins Chemical class 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
238000010000 carbonizing Methods 0.000 description 2
150000004035 chlorins Chemical class 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
229960003569 hematoporphyrin Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
229960000907 methylthioninium chloride Drugs 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
OSQUFVVXNRMSHL-LTHRDKTGSA-M sodium;3-[(2z)-2-[(e)-4-(1,3-dibutyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)but-2-enylidene]-1,3-benzoxazol-3-yl]propane-1-sulfonate Chemical compound [Na+].O=C1N(CCCC)C(=S)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 OSQUFVVXNRMSHL-LTHRDKTGSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000008791 toxic response Effects 0.000 description 2
229910052724 xenon Inorganic materials 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
IEDVQOXHVRVPIX-UHFFFAOYSA-N 2-(oxolan-2-yl)acetic acid Chemical compound OC(=O)CC1CCCO1 IEDVQOXHVRVPIX-UHFFFAOYSA-N 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000003763 carbonization Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000001044 red dye Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Landscapes

Radiation-Therapy Devices (AREA)

CA 578809 1987-10-01 1988-09-29 Technique de traitement photodynamique Expired - Fee Related CA1336504C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10331987A	1987-10-01	1987-10-01
US103,319		1987-10-01

Publications (1)

Publication Number	Publication Date
CA1336504C true CA1336504C (fr)	1995-08-01

Family

ID=22294549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 578809 Expired - Fee Related CA1336504C (fr)	1987-10-01	1988-09-29	Technique de traitement photodynamique

Country Status (1)

Country	Link
CA (1)	CA1336504C (fr)

1988
- 1988-09-29 CA CA 578809 patent/CA1336504C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2002-08-01	MKLA	Lapsed

Publication	Publication Date	Title
US4957481A (en)	1990-09-18	Photodynamic therapeutic technique
US6416531B2 (en)	2002-07-09	Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy
CA2182010C (fr)	2002-10-29	Ablation photochimique du tissu gastro-intestinal
McCaughan Jr et al.	1984	Palliation of esophageal malignancy with photoradiation therapy
AU684822B2 (en)	1998-01-08	Use of photodynamic therapy to treat prostatic tissue
CA2649368C (fr)	2018-03-20	Dispositif d'adaptateur de couplage de lumiere destine a une therapie photodynamique ou photothermique ou a un diagnostic photodynamique, ainsi que systeme et methode correspondants
Gatenby et al.	1987	CT-guided laser therapy in resistant human tumors: phase I clinical trials.
US7771426B2 (en)	2010-08-10	Bone treatment instrument and method
CA1336504C (fr)	1995-08-01	Technique de traitement photodynamique
RU2146159C1 (ru)	2000-03-10	Способ фотодинамической терапии злокачественных новообразований
Gatenby et al.	1987	Tumor therapy with hematoporphyrin derivative and lasers via a percutaneous fiberoptic technique: preclinical experiments.
RU2119363C1 (ru)	1998-09-27	Способ фотодинамической терапии опухоли
Berns et al.	1986	Porphyrin sensitized phototherapy
RU2169015C2 (ru)	2001-06-20	Способ фотодинамической терапии злокачественных опухолей
EP1166784B1 (fr)	2008-02-20	Inhibition de la restenose vasculaire apres une angioplastie
Jocham et al.	1984	Dye-laser-photoradiation-therapy of bladder cancer after photosensitization with hematoporphyrin derivative (HpD)-basis for an integral irradiation
RU2146160C1 (ru)	2000-03-10	Способ обезболивания при фотодинамической терапии злокачественных опухолей
Zorat et al.	1984	Hematoporphyrin phototherapy of malignant tumors
Huang et al.	2003	Studies of a novel photosensitizer Pd-bacteriopheophorbide (Tookad) for the prostate cancer PDT in canine model
Spinelli et al.	1991	Laserchemotherapy of tumours: clinical aspects
Huang et al.	0	Studies of a novel photosensitizer Pd-bacteriopheophorbide (Tookad